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Rationale
Patients seeking clinical treatment for urticaria, while pre-
senting with elevated inflammatory markers, were found
to be suffering from auto-inflammatory disorders, such as
Cryopyrin Associated Periodic Syndromes (CAPS), Famil-
ial Mediterranean Fever (FMF) and Schnitzler’s syndrome.
Patients were screened for, and/or began treatment with
canakinumab.
Methods
The 32 patients identified for investigation presented with
cases of chronic urticaria along with some of the following
symptoms: joint and bone pain, chills, conjunctivitis, peri-
odic fever, fatigue, weight loss, and hearing loss. 11
patients (34%) presented with Muckle-Wells syndrome.
Seven patients (22%) presented with Familial Cold Autoin-
flammatory Syndrome and a history of treatment with rila-
nocept. Three patients (9.5%) presented with FMF. Three
patients (9.5%) presented with Schnitzler’s syndrome.
Eight patients (25%) presented with undiagnosed forms of
CAPS. All patients showed elevated inflammatory mar-
kers, including Serum Amyloid A (SAA) and C-reactive
protein (CRP). Nine patients with Muckle-Wells syndrome
and a confirmed R260W mutation at the NLRP3 gene, and
one patient with an undiagnosed form of CAPS began
treatment with canakinumab. Patients received a 150 mg
treatment via sub-cutaneous injection every eight weeks.
Total injections to date for individual patients range from
two to seven. The remaining 22 patients are currently
being investigated for treatment with canakinumab.
Results
All ten patients treated with canakinumab experienced
remission within one week of their first injection. Remis-
sions were maintained by subsequent injections. Seven
patients with SAA levels >16,000 ng/mL (normal range
1000-5000 ng/mL) prior to treatment showed normal
SAA levels within one week of their first injection.
Conclusions
Canakinumab treatment for patients with Muckle-Wells
syndrome was associated with complete spontaneous
remissions within one week of commencing treatment,
and sustained clinical improvements over time. Patients
presenting with chronic urticaria should be carefully
assessed for disguised auto-inflammatory disorders,
through genetic testing and examination for elevated
inflammatory markers.
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